Champions in care Honoring healthcare providers who go above and beyond Explore BMS 2025 third quarter financial results Who I’m working for – and why it drives me every day Jim and …

In October, BMS announced it would acquire cardiology company MyoKardia for $13.1 billion ($225 per share) gaining control of mavacamten, a cardiovascular drug for obstructive …

3 days ago · Analysts had noted “unease” from investors regarding the state of the Phase III ADEPT-2 trial, with BMS at one point telling Leerink Partners that the reopening of enrollment …

Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures for a particular quarterly period are available on the company’s website at www.bms.com.

3 days ago · With the delay, BMS looks to finish 2025 without a much-needed comeback story for Cobenfy after another trial flop this spring for the drug as an adjunctive treatment for …

4 days ago · Bristol Myers Squibb (BMS) has delayed the data readout from the Phase III ADEPT-2 trial of Cobenfy (xanomeline/trospium chloride) after identifying site irregularities. The trial …

電池管理系統 （英語： Battery Management System，缩写 BMS）是管理可充電 二次電池 （多半是 鋰離子電池，也可能是 電池組）的電子系統，功能是讓電池在安全的操作條件下使用，避 …

Braine-l'Alleud, Belgium Function (s): Commercial Our site in the business park near Waterloo have anchored BMS’ commercial presence in Belgium and Luxembourg for over 40 years.

BMS is addressing some of the most complex diseases of our time, and our legacy in cancer, HIV and cardiovascular gives us confidence that we will continue rising to each challenge.

3 days ago · Study Continuation Follows Review of Site Level Data and Recommendation of Data Monitoring Committee BMS Remains Blinded to Study Data Bristol Myers Squibb (NYSE: …